About Rani Therapeutics
Rani Therapeutics is a company based in San Jose (United States) founded in 2012. Rani Therapeutics has raised $234.14 million across 9 funding rounds from investors including Novartis, Astrazeneca and Takeda Pharmaceuticals. The company has 105 employees as of December 31, 2024. Rani Therapeutics offers products and services including RaniPill, RT-111, and RT-102. Rani Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Adocia, BioAge Labs, Antag Therapeutics and Carmot, among others.
- Headquarter San Jose, United States
- Employees 105 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rani Therapeutics Holdings, Inc.
-
Annual Revenue
$1.03 M (USD)0as on Dec 31, 2024
-
Net Profit
-$30.02 M (USD)11.63as on Dec 31, 2024
-
EBITDA
-$48.57 M (USD)25.59as on Dec 31, 2024
-
Total Equity Funding
$234.14 M (USD)
in 9 rounds
-
Latest Funding Round
$60.26 M (USD), Post-IPO
Oct 23, 2025
-
Investors
Novartis
& 14 more
-
Employee Count
105
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rani Therapeutics
Rani Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RANI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Rani Therapeutics
Rani Therapeutics offers a comprehensive portfolio of products and services, including RaniPill, RT-111, and RT-102.
Capsule for oral administration of biologics to improve patient compliance.
Platform for oral ustekinumab delivery in clinical trials.
System for repeated oral biologic dosing in therapeutic applications.
People of Rani Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Rani Therapeutics
Rani Therapeutics has successfully raised a total of $234.14M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $60.26 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rani Therapeutics
Rani Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Astrazeneca and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on retail tech, mobile tech, and multiple sectors
|
Locked | Locked | Locked | |
|
Cathay Capital is engaged in global investment and transformation.
|
Locked | Locked | Locked |
Investor details for Rani Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rani Therapeutics
Investment portfolio details for Rani Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rani Therapeutics
Detailed financials for Rani Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rani Therapeutics Comparisons
Peer comparison for Rani Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rani Therapeutics
Rani Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Adocia, BioAge Labs, Antag Therapeutics and Carmot, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
Detailed competitors of Rani Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rani Therapeutics
Complete news archive for Rani Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rani Therapeutics
Rani Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Rani Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Talat Imran is the current CEO of Rani Therapeutics.
Rani Therapeutics is a funded company, having raised a total of $234.14M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Rani Therapeutics is 105.
Annual revenue of Rani Therapeutics is $1.03M as on Dec 31, 2024.
Rani Therapeutics was founded in 2012 in San Jose, United States, within the biotechnology sector. A proprietary platform is utilized to enable oral delivery of biologics for chronic disease treatment. The RaniPill capsule is designed for applications in conditions such as acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohns disease, hemophilia, and diabetes. Operations focus on advancing this delivery technology for broader therapeutic use.
Rani Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.
Rani Therapeutics offers RaniPill, RT-111, and RT-102.
Yes, Rani Therapeutics is publicly traded on NASDAQ under the ticker symbol RANI.
Rani Therapeutics has 15 investors. Key investors include Novartis, Astrazeneca, Takeda Pharmaceuticals, Cathay Financial Holdings, and Stevanato Group.
The ticker symbol of Rani Therapeutics is RANI on NASDAQ.